However, secondary resistance mutations in SMO or genetic alterations of downstream HH target genes have been identified only in a subset of resistant MB and BCC tumors and failed to explain the emergence of resistance towards SMO inhibitors in other types of cancer. Here, SMO is linked to cancer.